Blog

In the relentless fight against cancer, immunotherapy has emerged as a beacon of hope, harnessing the body's own defenses to combat malignant cells. Yet, predicting which patients will respond to these groundbreaking treatments remains a critical challenge. Recent scientific breakthroughs are now pointing towards an unexpected ally in this quest: IgG1 plasma cells, revealing their potential as a powerful new biomarker to forecast the success of cancer immunotherapy. Introduction Immunotherapy, particularly immune checkpoint blockade (ICB), has revolutionized cancer treatment, offering durable responses for many patients. However, a significant portion of individuals do not benefit, undersco …